The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
Abstract
BACKGROUND: Transthyretin (TTR) amyloidosis is a rare, life-threatening, systemic, autosomal dominant condition occurring in adults, with two main forms: hereditary (associated with TTR gene mutations) and wild-type. Studies indicate considerable heterogeneity in disease presentation, with predominantly polyneuropathic, predominantly cardiac, or mixed phenotypes. METHODS: THAOS - the Transthyretin Amyloidosis Outcomes Survey - is the first global, multicenter, longitudinal, observational survey that collects data on the natural history of TTR amyloidosis (ClinicalTrials.gov: NCT00628745). This paper presents data on signs and symptoms, neurological and cardiac assessments, biomarkers and quality of life in the patients enrolled in THAOS from its inception in December 2007 to September 2011. RESULTS: At the time of this analysis, data were available from 611 symptomatic patients with hereditary TTR amyloidosis, 67 symptomatic patients with wild-type TTR amyloidosis, and 274 currently asymptomatic individuals with a TTR mutation. Nineteen countries were participating in the registry. The largest patient groups came from Portugal (n = 453), the USA (n = 129), Italy (n = 70), and Japan (n = 68). Predominant symptom presentation in patients with hereditary TTR amyloidosis differed according to the underlying disease-causing mutation (polyneuropathy for Val30Met, cardiomyopathy for Val122Ile and Leu111Met, and mixed for Glu89Gln). However, each mutation was associated with clear multisystem involvement. Similarly, although cardiomyopathy was predominant in patients with wild-type TTR amyloidosis, many also showed symptoms consistent with neuropathy. Quality of life in patients with hereditary TTR amyloidosis, but not asymptomatic carriers of disease-causing mutations, was severely impaired relative to that of the age-matched general US population. CONCLUSIONS: This preliminary analysis highlights the considerable phenotypic heterogeneity for neurological and cardiac manifestations in patients with hereditary and wild-type TTR amyloidosis and the necessity of providing multidisciplinary care. THAOS registry data will help better characterize the diverse presentation and course of TTR amyloidosis worldwide and aid in improving and standardizing diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Falk, R. H., Comenzo, R. L., & Skinner, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371306 · Cited by 1,180
Breathnach, S. M. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)70001-8 · Cited by 615
Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., & Buxbaum, J. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702133360703 · Cited by 554
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2003) · Science · doi:10.1126/science.1079589 · Cited by 525
Tabulation of human transthyretin (TTR) variants, 2003
Connors, L. H., Lim, A., Prokaeva, T., Roskens, V. A., & Costello, C. E. (2003) · Amyloid · doi:10.3109/13506120308998998 · Cited by 505
The molecular biology and clinical features of amyloid neuropathy
Benson, M. D., & Kincaid, J. C. (2007) · Muscle & Nerve · doi:10.1002/mus.20821 · Cited by 447
Transthyretin-Related Familial Amyloidotic Polyneuropathy
Ando, Y., Nakamura, M., & Araki, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1057 · Cited by 416
Glynn, L. E. (1981) · PubMed Central · Cited by 412
A National Catalog of Preference-Based Scores for Chronic Conditions in the United States
Sullivan, P. W., Lawrence, W. F., & Ghushchyan, V. (2005) · Medical Care · doi:10.1097/01.mlr.0000172050.67085.4f · Cited by 388
Cited by
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Self-citationDiagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis
Gertz, M. A., Benson, M. D., Dyck, P. J., Grogan, M., Coelho, T., Cruz, M., Berk, J. L., Plante-Bordeneuve, V., Schmidt, H. H. J., & Merlini, G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.075 · Cited by 475
Self-citationVutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Fontana, M., Berk, J. L., Gillmore, J. D., Witteles, R. M., Grogan, M., Drachman, B., Damy, T., Garcia-Pavia, P., Taubel, J., Solomon, S. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409134 · Cited by 462
Self-citationPatisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300757 · Cited by 339
Self-citationSystemic amyloidosis from A (AA) to T (ATTR): a review
Muchtar, E., Dispenzieri, A., Magen, H., Grogan, M., Mauermann, M., McPhail, E. D., Kurtin, P. J., Leung, N., Buadi, F. K., Dingli, D., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13169 · Cited by 327
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans
Quarta, C. C., Buxbaum, J. N., Shah, A. M., Falk, R. H., Claggett, B., Kitzman, D. W., Mosley, T. H., Butler, K. R., Boerwinkle, E., & Solomon, S. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404852 · Cited by 263
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
Judge, D. P., Heitner, S. B., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., Grogan, M., Selby, V. N., Jacoby, D., Hanna, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.012 · Cited by 263
Self-citationUrits, I., Swanson, D., Swett, M. C., Patel, A., Berardino, K., Amgalan, A., Berger, A. A., Kassem, H., Kaye, A. D., & Viswanath, O. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00208-1 · Cited by 262
Castaño, A., Drachman, B. M., Judge, D., & Maurer, M. S. (2015) · Heart Failure Reviews · doi:10.1007/s10741-014-9462-7 · Cited by 254
Self-citationTransthyretin: A multifaceted protein
Vieira, M., & Saraiva, M. J. (2014) · BioMolecular Concepts · doi:10.1515/bmc-2013-0038 · Cited by 185
“The genetic defect in these Portuguese families has been ascribed to a single point mutation in the TTR gene, originating a mutant TTR (TTR Val30Met) by far, the most frequent TTR mutation associated with FAP in Portugal and elsewhere (118).”
BackgroundAdams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30368-9 · Cited by 158
Self-citationAdvances in the treatment of hereditary transthyretin amyloidosis: a review
Gertz, M. A., Mauermann, M. L., Grogan, M., & Coelho, T. (2019) · Brain and Behavior · doi:10.1002/brb3.1371 · Cited by 102
Self-citationGertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1635008 · Cited by 38
Metadata
- Authors
- Coelho, T., Maurer, M. S., & Suhr, O. B.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2012-12-13
- Volume
- 29
- Issue
- 1
- Pages
- 63-76
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2118369819
- Cited by
- 339
- References
- 24
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.